Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017
October 31 2017 - 3:00AM
Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative therapies for respiratory diseases,
announces today that it will report its financial results for the
three months ended September 30, 2017 on Tuesday, November 7, 2017.
Verona Pharma will host an investment community
conference call at 8:00 a.m. Eastern Standard Time (1:00 pm
Greenwich Mean Time) on November 7, 2017 to discuss the third
quarter financial results and provide a clinical development
update.
Analysts and investors may participate in the
conference call by utilizing the conference ID: 1550110 and dialing
the following numbers:
- (877)280-1254 or (646)254-3388 for callers in the United
States
- 0800 279 5736 or 44(0)20 3427 1901 for callers in the United
Kingdom
- 0800 589 2673 or 49(0)69 2222 10619 for calls in Germany
Those interested in listening to the conference
call live via the internet may do so by visiting the “Investors”
page of Verona Pharma’s website at www.veronapharma.com and
clicking on the webcast link.
A webcast replay of the conference call [audio]
will be available on the “Investors” page of Verona Pharma’s
website at www.veronapharma.com.
About Verona Pharma plc
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of respiratory diseases with
significant unmet medical needs. Verona Pharma’s product candidate,
RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes
phosphodiesterase 3 and 4 that acts as both a bronchodilator and an
anti-inflammatory agent in a single compound. In clinical trials,
treatment with RPL554 has been observed to result in statistically
significant improvements in lung function as compared to placebo,
and has shown clinically meaningful and statistically significant
improvements in lung function when administered in addition to
frequently used short- and long-acting bronchodilators as compared
to such bronchodilators administered as a single agent. Verona
Pharma is developing RPL554 for the treatment of chronic
obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and
potentially asthma.
For further information, please
contact:
Verona Pharma plc |
Tel:
+44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer |
info@veronapharma.com |
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and UK
Broker) |
Tel: +44
(0) 20 7710 7600 |
Stewart Wallace / Jonathan Senior / Ben Maddison |
SNELVeronaPharma@stifel.com |
|
|
FTI
Consulting (UK Media and Investor enquiries) |
Tel:
+44 (0)20 3727 1000 |
Simon
Conway / Natalie Garland-Collins |
veronapharma@fticonsulting.com |
|
|
ICR,
Inc. (US Media and Investor enquiries) |
Tel: +1
203-682-8251James.Heins@icrinc.com |
James
Heins |
Stephanie Carrington |
Tel.
+1 646-277-1282Stephanie.Carrington@icrinc.com |
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024